{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030374","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.146224+00:00","generated_at":"2026-06-22T10:03:21.132401+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Abeona raises $35M in private placement; Phase 3 EB-101 trial meets endpoints","bullets":["Gross proceeds of $35M from sale of 7.07M shares, pre-funded warrants for 0.54M shares, and common warrants for 7.61M shares.","Offering price per unit $4.60; common warrants exercisable at $4.75 per share for five years.","Phase 3 VIITAL trial for EB-101 met co-primary, secondary, and exploratory endpoints with high statistical significance.","Net proceeds plus existing resources expected to fund operations into Q3 2024.","Placement includes new and existing investors: Adage Capital, Armistice Capital, Deerfield, EcoR1, Nantahala."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030374","json":"https://secwatch.observer/filing/0001493152-22-030374.json","markdown":"https://secwatch.observer/filing/0001493152-22-030374.md","text":"https://secwatch.observer/filing/0001493152-22-030374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/0001493152-22-030374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T10:03:21.132401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c36cc18a2c791bdfaf8f9d6b76ef375ed21fe3b7","claim":"ABEONA THERAPEUTICS INC. entered into Securities Purchase Agreement with a group of investors (the “Purchasers”) valued at approximately $35.0 million (effective 2022-11-03).","evidence_excerpt":"Abeona Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a group of investors (the “Purchasers”) providing for the private placement (the “Private Placement”) to the Purchasers of (i) 7,065,946 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) (ii) pre-funded warrants to purchase 543,933 shares of Common Stock with a term of five years from the issuance date (the “Pre-Funded Warrants”) and (iii) warrants to purchase 7,609,879 shares of Common Stock with a term of five years from the issuance date (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”), for an aggregate purchase price of approximately $35.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/0001493152-22-030374-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a group of investors (the “Purchasers”)"},{"label":"Value","value":"approximately $35.0 million"},{"label":"Effective","value":"2022-11-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}